Contact Us
Drug Search Results
More Filters [+]

Neramexane

Alternative Names: neramexane
Latest Update: 2023-08-02
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: NMDA Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merz
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Neramexane

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Tinnitus|Alzheimer Disease

Phase 2: Nystagmus, Pathologic|Multiple Sclerosis|Tinnitus|Nystagmus, Congenital|Chronic Pain|Cancer Pain|Pain, Postoperative|Acute Pain

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2011-004998-83

P2

Completed

Unknown

2013-07-09

OLLTT

P3

Terminated

Tinnitus

2011-12-01

2008-001432-13

P3

Terminated

Tinnitus

2011-10-12

2009-011246-25

P3

Completed

Tinnitus

2011-06-03

Recent News Events

Date

Type

Title

08/02/2023

PubMed

 Literature-Based Discovery Predicts Antihistamines Are a Promising Repurposed Adjuvant Therapy for Parkinson's Disease.

08/13/2021

PubMed

 Efficacy of pharmacologic treatment in tinnitus patients without specific or treatable origin: A network meta-analysis of randomised controlled trials.

10/18/2019

News Article

 Global Tinnitus Pipeline Insights 2019

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions